A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS

NCT03884829 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

7

Enrollment

INDUSTRY

Sponsor class

Stopped Switch to oral formulation of CYC140 (plogosertib)

Conditions

AML, Adult
Myelodysplastic Syndromes
ALL, Adult
CML, Refractory
CLL, Refractory

Interventions

DRUG: CYC140

Sponsor

Cyclacel Pharmaceuticals, Inc.

Collaborators

[object Object]